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The Developmental Regulator Pax6 Is Essential for
Maintenance of Islet Cell Function in the Adult Mouse
Pancreas
Alan W. Hart, Sebastien Mella, Jacek Mendrychowski, Veronica van Heyningen, Dirk A. Kleinjan*
Medical Research Council Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom
Abstract
The transcription factor Pax6 is a developmental regulator with a crucial role in development of the eye, brain, and olfactory
system. Pax6 is also required for correct development of the endocrine pancreas and specification of hormone producing
endocrine cell types. Glucagon-producing cells are almost completely lost in Pax6-null embryos, and insulin-expressing beta
and somatostatin-expressing delta cells are reduced. While the developmental role of Pax6 is well-established, investigation
of a further role for Pax6 in the maintenance of adult pancreatic function is normally precluded due to neonatal lethality of
Pax6-null mice. Here a tamoxifen-inducible ubiquitous Cre transgene was used to inactivate Pax6 at 6 months of age in
a conditional mouse model to assess the effect of losing Pax6 function in adulthood. The effect on glucose homeostasis and
the expression of key islet cell markers was measured. Homozygous Pax6 deletion mice, but not controls, presented with all
the symptoms of classical diabetes leading to severe weight loss requiring termination of the experiment five weeks after
first tamoxifen administration. Immunohistochemical analysis of the pancreata revealed almost complete loss of Pax6 and
much reduced expression of insulin, glucagon, and somatostatin. Several other markers of islet cell function were also
affected. Notably, strong upregulation in the number of ghrelin-expressing endocrine cells was observed. These findings
demonstrate that Pax6 is essential for adult maintenance of glucose homeostasis and function of the endocrine pancreas.
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Introduction
Maintenance of glucose homeostasis is essential for life and
health. The regulation of blood sugar levels is achieved by peptide
hormone secretion from the endocrine cells of the pancreas,
located in the islets of Langerhans. Dysfunction or destruction of
pancreatic b-cells leads to diabetes mellitus, and better un-
derstanding of the factors required for maintenance of functional
islet cells is of great medical importance. Over the past two
decades the identity and role of different transcription factors and
cell markers for pancreas development has become increasingly
well-defined, and significant insight has been achieved into the
combinations and interactions of regulatory factors required at
different stages [1–3]. The paired and homeodomain containing
transcription factor Pax6 plays a key role in the development of the
endocrine pancreas, in addition to its more widely known role in
eye, brain and olfactory system development [4]. Well-defined
disease phenotypes have been described in mammals carrying
heterozygous loss of function mutations. Homozygotes die neo-
natally with absent eyes and olfactory bulbs, with brain
malformations, as well as pancreatic insufficiency [5,6]. Pax6 is
required for the correct development and spatial organisation of
all islet cell precursors [6,7], following full endocrine progenitor
cell commitment triggered by the expression of high levels of Ngn3
[8]. Pax6 has been shown to be regulated by Pdx1 [9] and in
zebrafish the pax6b gene was demonstrated to be a direct pdx1
target [10]. Pax6 is subsequently required for the differentiation of
alpha cells [11]. Once the different endocrine cell types of the islet
are defined, Pax6 expression is necessary to control the precise
expression of each endocrine hormone: glucagon, insulin,
somatostatin and pancreatic polypeptide [7,12]. The more re-
cently identified epsilon cells, derived from Ngn3-positive endo-
crine precursors that have turned off Pax4 and Nkx2.2 [13,14],
produce the 28 amino acid orexigenic peptide ghrelin. A
proportion of alpha cells co-express ghrelin with glucagon. All
the endocrine cells carry secretagogue receptors for ghrelin, which
modulate endocrine hormone production. Towards the end of the
fetal stage the pancreas is the major source of ghrelin. Ghrelin is
also produced in the stomach, intestine and brain [15], and in
adult life these tissues are the major sites of production, while there
remain very few, if any ghrelin producing cells in the adult
pancreas [14]. Ghrelin-expressing cells are greatly increased while
different endocrine cell types are depleted in the developing
pancreas of Pax6-null, Pax4-null or Nkx2.2-null mice [13,14].
It is becoming increasingly clear that many key developmental
regulators fulfill multiple roles at different stages of development,
in the progression from initiation to commitment, differentiation
and maturation of cell types [3,16]. Once development has been
completed and the adult complement of cells established, a re-
quirement for tissue maintenance and regeneration may persist.
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The later role of developmentally acting transcription factors that
continue to be expressed into adulthood remains poorly explored.
However, there is evidence, for example for Pdx1 [17] and for the
non-pancreas-expressed gene Sox2 [18], that such genes also
function in tissue maintenance. Pax6 is expressed in a number of
adult tissues, including pancreatic islet cells [19,20,21], as well as
brain [22], olfactory [23] and ocular cells [24]. Functional deficits
in PAX6-expressing tissues have been observed in patients with
PAX6 haploinsufficiency, most notably associated with the
developmental eye anomaly aniridia (absence of the iris), where
corneal limbal stem cell defects [25] and deficits of olfactory
function and neurological organisation [26] have been reported
[22]. There have also been reports of glucose intolerance and
predisposition to diabetes in some individuals, and in some rodent
models, with heterozygous PAX6 mutations [19,20,21,27,28].
Because of the multiple essential functions fulfilled by Pax6 during
development, it is difficult to dissect its role in adult tissues where
Pax6 expression is maintained.
Here we have made use of a conditional Pax6 mouse mutant in
which exons 5–6 are flanked by LoxP sites [29], crossed with an
inducible Cre deletor strain [30] to study the potential role of Pax6
in adult tissue maintenance. Cre-mediated deletion of Pax6 in
healthy adult mice was activated at 6 months of age. We show that
the loss of Pax6 leads to a rapid appearance of diabetic symptoms
and strong deterioration in health within a few weeks. A number of
pancreatic hormones, transcription factors and insulin processing
enzymes are affected by the loss of Pax6, demonstrating an
essential role for Pax6 in the continued maintenance of pancreas
function in adult life.
Materials and Methods
Ethics Statement
This study was approved by the University of Edinburgh ethical
committee (approval ID TR-18-07) and performed under UK
Home Office license number PPL 60/3785. Animals were cared
for in accordance with the guidelines for animal care and
experimentation of the University of Edinburgh. All animals were
monitored twice daily by visual inspection and by weekly weight
measurements. Every effort was made to minimize suffering. The
experiment was terminated when weight loss in the CPTD6
(CreTM-Pax6 floxed-Tamoxifen-Diabetic) mice approached 20%
of starting body weight.
The Pax6flox mice were kindly provided by Drs Ian Simpson and
David Price. The Pax6flox, Pax6lacZ and CAGGCreERTM transgenic
lines have been published previously [6,29,30]. Mice were kept on
CD1 or hybrid B6CBAF1 background. Figure 1 shows the
combinations of alleles generated.
Tamoxifen Injections
Intraperitoneal injections of corn oil only (control animals) or
corn oil (glycerol trio-octonoate, Sigma C8267) containing
dissolved Tamoxifen (Sigma T5648) (100 microgram/gram body
weight) were administered to six month-old mice daily for 5
consecutive days. Prior to injection each animal was weighed and
the injection volume of a 20 mg/ml tamoxifen stock solution or of
corn oil alone adjusted accordingly.
Glucose Tolerance Tests
Animals were fasted for five hours prior to intraperitoneal
injection of 2 g glucose (Sigma) per kilogram of body weight.
Blood was drawn from the tail vein at 0, 15, 30, 60, 90, and 120
minutes after injection and glucose values were monitored using
an automatic glucometer (Accuchek, Roche).
Urine Glucose Tests
Urine glucose levels were monitored weekly. Urine was
collected from the animal and dropped onto a Diastix (Bayer)
glucose stick. In accordance with the manufacturers’ instructions
the result was recorded by photography after 30 seconds
incubation. Darkening of the glucose sensitive area on the stick
indicates an elevated urine glucose level that is compared to
a standard series provided by the manufacturer.
Immunofluorescence/immunohistochemistry
Tissues were fixed in 4% paraformaldehyde (PFA) for 3–6 hours
at room temperature and then embedded in either paraffin or
Tissue-Tek freezing solution. Sections were cut using a microtome
or cryostat and 5–10mm sections were collected onto Superfrost
slides. Microwave antigen retrieval with 10 mM Sodium Citrate
(pH 6) was used to unmask the antigen prior to incubation in
blocking solution of PBS/0.1% sheep serum. Primary antibodies
were incubated overnight at 4uC and secondary antibodies for 60
minutes at room temperature. The following antibodies were used:
Pax6 (Abcam), Insulin (Dako), Glucagon (Dako), Somatostatin
(Dako), PC1/3 (Pcsk1; Enzo), PC2 (Pcsk2; Enzo), Isl1 (kind gift
Helena Edlund), Pdx1 (Ipf1; kind gift Helena Edlund), Glut2
(Slc2a2; kind gift Helena Edlund), Ghrelin (Santa Cruz), Amylase
(Sigma), Nkx2.2 (DSHB), Nkx6.1 (DSHB). Alexa594 conjugated
secondary antibody (Invitrogen), FITC conjugated secondary
antibody (Jackson ImmunoResearch).
Quantification of Islet Cell Populations
Quantification of numbers of hormone producing cells relative
to the total islet cell number was performed using the cell counter
plug-in of Image J software (http://imagej.en.softonic.com/).
Hormone expressing cells (insulin, glucagon, somatostatin and
ghrelin) were visualised by their immunofluorescent marker and all
cells stained above background were counted as positive. Total
islet cell numbers were obtained by visualisation with DAPI
staining. Cell numbers were counted on sections from at least 4
different control and CPTD animals each. Total cell numbers
counted for presence of hormone expression were: Insulin (2209
control, 3398 CPTD6), Glucagon (2087 control, 2297 CPTD6),
Somatostatin (4122 control, 4889 CPTD6), Ghrelin (2193 control,
3145 CPTD6). Raw cell counts were analysed in Excel and
statistical analysis was done using a students t-test. Quantifications
were performed on pancreatic sections from four different animals
for each group (control and CPTD6).
Results
Generating Animals of Required Genotypes
The timeline of the experiment is schematically represented in
figure 1A. To generate mice of the required genotypes floxed Pax6
animals (Pax6flox/+) were crossed with CAGGCreERTM transgenic
mice to generate Pax6flox/+//CAGGCreERTM mice. These were
then crossed to heterozygous Pax6flox/+ or Pax6LacZ/+ mice to
generate animals of the desired genotypes (Figure 1B). Animals
were genotyped by PCR (details available on request). Two sets of
controls were included: 1. ‘‘Oil control’’, a set with the designated
genotypes including animals with and without the CAGGCreERTM
transgene, injected with corn oil only. 2. ‘‘Tamoxifen control’’,
a second set containing heterozygous and wild-type mice, with and
without the CAGGCreERTM transgene, injected with Tamoxifen.
The experimental group, designated ‘‘CPTD6’’, consisted of
Pax6flox/Pax6flox or Pax6flox/Pax6lacZ mice carrying the CAGG-
CreERTM transgene and injected with Tamoxifen.
Pax6 in Pancreatic Islet Cell Maintenance
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Figure 1. Experimental procedure used to investigate the role of Pax6 in the adult mouse pancreas. (A) Timeline of the experiment.
Mice were bred to obtain the various experimental and control genotypes. After a pre-experimental period of 6 months (indicated by the period to
the left of timepoint = 0 weeks) all mice received daily injections, with tamoxifen or oil only, on 5 consecutive days during week 1. Blood glucose level
and glucose tolerance measurements were carried out in the week prior to the injections and in the final week (week 5). All mice were sacrificed at
the end of week 5 and tissues were fixed for immunohistochemistry (B) Schematic representation of the combinations of genotypes and treatments
Pax6 in Pancreatic Islet Cell Maintenance
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Assessment of Initial Metabolic Status
To obtain baseline data the animals were weighed on a weekly
basis (Figure 1C) and their general health assessed from 4 weeks
prior to injections. No significant difference in weight between the
control and experimental groups (Figure 1C) was observed. In
addition, one week prior to injection (Week -1), urine glucose
measurement, fasting blood glucose and glucose tolerance tests
were performed (Figure 2A, B, C). Glucose was not detected in
urine samples from any animal in either the control or the
experimental groups (Figure 2A). Fasting blood glucose levels were
similar in both controls and CPTD6 mice (Figure 2B, white bars).
However, the glucose tolerance test (Figure 2C) revealed slight
intolerance in the CPTD6 group with the area under the curve
approximately 1.5 fold higher than in control animals (n = 5,
CPTD6, n= 12 Oil control, n = 7 Tamoxifen control). The
animals in the CPTD6 group were a combination of Pax6flox/
Pax6flox//CAGGCreERTM and Pax6flox/Pax6lacZ//CAGGCreERTM,
but were predominantly the latter genotype (2+3), therefore
carrying only one functional copy of Pax6, and this may account
for this observation by itself, or could suggest a slight leakiness of
the CAGGCreERTM transgene to which Pax6flox/Pax6lacZ would be
more susceptible.
Five daily intraperitoneal injections of corn oil or Tamoxifen (in
corn oil) were administered, and animals were weighed daily at
this stage. Animals in all three groups experienced a similar weight
loss over this five day period (Figure 1C). Both control groups and
the CPTD6 experimentals recovered and had gained several
grams of body weight by 7 days after the last injection. The weight
gain continued through the second and subsequent weeks for all
control mice, however at 14 days after the last injection the
CPTD6 mice were losing weight again. This weight loss in the
CPTD6 mice continued until termination of the experiment 4
weeks after the last injection of Tamoxifen (Figure 1C).
Effect of Pax6 Inactivation on Glucose-handling
Non-fasting urine samples continued to be monitored from
Week 1 (day of final injection), at weekly intervals. None of the
control mice (Oil control and Tam control) had detectable levels of
glucose in their urine at any stage. In contrast at week 3, just over
two weeks after the last injection the CPTD6 mice presented with
a positive urine glucose test, with concentrations greater than 2%
(.11.1 mM; see Methods) which was maintained at week 4 and 5
(Figure 2A). Fasting blood glucose was measured at the beginning
of week 5 followed by a glucose tolerance test. The CPTD6 mice
presented with a mean elevated fasting blood glucose level of
23.4 mM compared with oil injected control mice with 5.9 mM
and tamoxifen injected control mice with 6.4 mM (Fig. 2, n= 5,
n = 12, n = 7, P,0.05) (Figure 2B, black bars). The elevated fasting
blood glucose was accompanied by an impaired ability to clear
glucose when challenged with glucose resulting in a 3 fold
increased area under the glucose tolerance test curve of CPTD6
mice as compared to all control mice (Figure 2D, n= 5, n= 19).
CPTD6 mice were also observed to drink and urinate more,
indicating the CPTD6 animals presented all classical symptoms of
diabetes: weight loss, polydypsia, polyuria, glycosuria and elevated
fasting blood glucose levels.
Immunohistochemical Analysis of Pancreas
All animals were sacrificed at the end of week 5 (i.e. 4 weeks
after the final tamoxifen injections) and their pancreata fixed and
analysed for expression of a number of pancreatic markers,
including several pancreatic transcription factors, endocrine
hormones and processing enzymes.
Pax6 expression was severely diminished. To assess the
efficiency of the Cre mediated inactivation of the Pax6 gene, the
first marker to be tested was Pax6 itself (Fig. 1D), revealing a loss of
detectable protein in most islet cells of the CPTD6 mice (n = 4).
Some residual expression was observed in a small number of
individual CPTD6 islet cells, while in controls (n = 4) clear nuclear
staining was observed in all islet cells. These data show that the
CreERTM protein was successfully activated by the tamoxifen
treatment in the large majority of islet cells, resulting in excision of
the floxed Pax6 allele and loss of Pax6 production from the
inactivated allele. DAPI staining of CPTD6 pancreata showed the
distinct organisation of endocrine cells into islet-like structures was
maintained, although many islets presented with a less organized,
round/oval structure compared to the more elongated architec-
ture seen in control islets.
Expression of endocrine hormones in CPTD6
islets. Immunohistochemical analysis revealed both insulin
(Figure 3A, B) and glucagon (Figure 3C, D) expression were
severely reduced in the CPTD6 animals. For both hormones the
number of expressing cells was much reduced, and co-staining
revealed altered islet architecture with a cells appearing in more
internal positions in the CPTD6 islet (Figure 3C, D). Control islets
show the normal islet architecture with b cells at the centre
surrounded by a mantle of a cells. A moderate reduction in the
number of somatostatin-expressing cells was also detected
(Figure 3E, F).
Expression of key pancreatic transcription
factors. Expression of Islet1 (Isl1), an important regulator for
pancreas development, showed no significant difference between
control and CPTD6 mice and confirmed that islet cells were still
present in the CPTD6 animals (Figure 4A, B). Similarly the
expression of Nkx2.2 appeared unaffected in the CPTD6 islets
(Figure 4C, D). In contrast, the adult b-cell marker Nkx6.1
(Figure 4E, F) was downregulated in the absence of Pax6.
Interestingly, Pdx1, which is required for pancreas development
and b-cell function, was also severely downregulated in the
CPTD6 animals with very few islets showing prominent levels of
Pdx1 expression (Figure 4G, H). As previous work has shown
a requirement for Pdx1 expression in adult b-cells for maintenance
of glucose sensing and the proinsulin-processing machinery [31],
we next analysed the status of some key components [31].
Analysis of additional key islet cell markers. Glut2
(Slc2a2), a glucose transporter that is required post-prandial to
sense glucose fluctuations, is expressed at the surface membrane of
adult b-cells. Glut2 expression was almost completely abolished in
(oil or tamoxifen injection) of all animals used in the study. Animals were sorted into control (oil only control or Tamoxifen control) or CPTD6
(CreERTM-floxed Pax6-Tamoxifen-Diabetic) groups. (C) Graph showing male mouse body weights from 4 weeks pre-treatment until 5 weeks post-
treatment, with a time-line of the procedure shown at the top. All animals exhibited healthy body weight prior to treatment. During the 5 day period
of daily injections all animals lost some weight, but recovered in the week following the injections. While control animals continued to gain weight
and were back to pre-treatment body weight at termination, CPTD6 animals began to lose weight again from the second week post-treatment
onwards until termination of the experiment. Data are shown as mean 6 SEM (Standard error of the mean). (D) Immunohistochemistry for Pax6 was
used to assess the efficiency of the Cre-mediated deletion of Pax6, by staining for the presence or absence of Pax6. Control animals show nuclear
Pax6 immuno-reactivity in the pancreatic islet cells. The CPTD6 islets show absence of Pax6 immuno staining in the large majority of cells, indicating
successful Cre-mediated inactivation of the Pax6 gene. Scale bar, 50 mm.
doi:10.1371/journal.pone.0054173.g001
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the CPTD6 animals compared with controls (figure 5A, B). Insulin
is processed from a larger precursor, proinsulin through a regulated
secretory pathway and stored in secretory granules in readiness for
secretion as active insulin. A number of proteins are required for
proinsulin processing into its active disulphide bond linked A and
B chains. Two of these, PC1/3 (Pcsk1) and PC2 (Pcsk2), act in
concert with additional proteins to cleave proinsulin at specific
dibasic residue junctions to produce equimolar amounts of active
insulin and C-peptide. Immunohistochemical analysis of PC1/3
(figure 5C, D) revealed that expression of this enzyme is strongly
reduced in the CPTD6 animals, although some cells within the
islet maintain high levels of PC1/3 expression. In contrast, PC2
expression does not appear to be affected (Figure 5E, F).
Exocrine pancreas. Gross histology of the exocrine pancreas
from CPTD6 mice suggested a slight difference from controls,
showing a less organised and looser architecture with fewer acinar
structures and a more prominent ductal network. Nevertheless, the
CPTD6 exocrine pancreas showed normal positive staining for
amylase expression (Figure 5G, H), presenting the same punctuate
expression pattern in acinar structures as control pancreata
(CPTD6, n= 4, controls, n = 4).
Strong upregulation of ghrelin in CPTD6 islets. In
contrast to the loss of classical hormone production in a, b and
d cells (Figure 6A, D, G, J, M, P), a large increase in ghrelin
positive cells was observed in CPTD6 islets. Ghrelin positive cells
are very rare or absent in a normal adult pancreas, as illustrated by
the controls studied here (Figure 6B, H, N), but the CPTD6 islets
Figure 2. Assessment of glucose handling in control and CPTD6 mice. (A) Urine glucose levels were tested weekly using Diastix (Bayer) test
sticks from week 0 (before first injection) to termination of the experiment (week 5). CPTD6 mice presented with glucose in their urine when tested 3
weeks post first injection. None of the control animals (tamoxifen- nor oil-injected controls) showed glucose in their urine at any time. (B) Fasting
blood glucose levels were normal in all three experimental groups in the week prior to the tamoxifen/oil injections (white bars). When tested again in
the final week of the experiment (start of week 5) CPTD6 mice presented with hyperglycaemia (black bars) (C). A glucose tolerance test performed in
the week before injection revealed slight glucose intolerance in CPTD6 mice compared to the control animals. (D) Glucose intolerance of the CPTD6
mice was exacerbated post injection. Data are shown as mean 6 SEM.
doi:10.1371/journal.pone.0054173.g002
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exhibit large numbers of ghrelin positive cells, located pre-
dominantly in the periphery of the islets (Figure 6E, K, Q). Co-
expression studies for ghrelin with insulin, glucagon or somato-
statin (Figure 6C, F, I, L, O, R) reveal that the ghrelin positive cells
do not express any of these three hormones, and should therefore
be classified as e cells. To obtain a quantitative measure of the
differences in the numbers of hormone producing cells in the
pancreatic islets of CPTD6 and control animals, the percentage of
hormone expressing cells per islet was determined. Hormone
expressing cells were identified by immunofluorescence and
counted relative to the total number of DAPI positive cells in
the islet. The average percentage of insulin positive cells per islet
was decreased from 72% in the controls to 19% in CPTD6
animals, while the percentage of glucagon expressing cells
decreased from 11.4% to 5.3%. A more modest change was seen
in somatostatin positive cell numbers (11.6% in controls versus
9.5% in CPTD6). In contrast the percentage of ghrelin expressing
cells showed a large increase from 0.6% in controls to 20.6% in
CPTD6 pancreatic islets.
Discussion
The developmental regulator Pax6 has a well-established role in
the embryonic development of the endocrine pancreas and the
correct differentiation of the different cell types in the islets of
Langerhans. The data presented here show that there is
a continued requirement for Pax6 in the adult to maintain a fully
functioning endocrine pancreas. Pax6 is essential for development
of the eye and brain, and homozygous loss of function results in
neonatal lethality, precluding the analysis of the potential
importance of Pax6 gene function in the tissues in which it
Figure 3. Expression analysis of pancreatic endocrine hor-
mones. Images show immuno-stainings for insulin (A, B), glucagon (C,
D), and somatostatin (E, F) in sections through the pancreas of control
(A, C, E) and CPTD6 (B, D, F) mice sacrificed 5 weeks post-injections.
Insulin expression is almost completely abolished in CPTD6 islets
compared with control islets (A, B). The number of cells staining
positive for glucagon is also decreased in the CPTD6 islets compared to
controls (C, D). Somatostatin expression is more moderately reduced in
the CPTD6 islets with most CPTD6 islets showing fewer positive cells
compared to the controls. (E, F). Images are representative of at least
four animals from each group. Scale bar, 50 mm.
doi:10.1371/journal.pone.0054173.g003
Figure 4. Expression analysis of key transcription factors.
Immunohistochemistry was performed in control (A, C, E, G, I, K) and
CPTD6 (B, D, F, H, J, L) mice. (A, B) Nuclear expression of the pancreatic
islet marker Islet 1 (Isl1) is retained in CPTD6 mice, showing that the islet
cells are present. (C,D) Expression of Nkx2.2 is also unaffected in CPTD6
mice. (E, F) In contrast expression of Nkx6.1 is reduced in Pax6 deficient
cells. (G, H) The nuclear expression of the transcription factor Pdx1 is
lost in CPTD6 mice. Images are representative of at least four animals
from each group. Scale bars, 50 mm.
doi:10.1371/journal.pone.0054173.g004
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remains expressed in adulthood. To bypass this problem we have
studied the effect of loss of Pax6 in adult mice in a conditional
Pax6 deletion model crossed with a tamoxifen inducible Cre
deletor strain. In this way we were able to remove most functional
Pax6 in mice that had lived a healthy life for the 6 months leading
up to the experiments. Remarkably the deletion of Pax6 led to
a rapid development of diabetic symptoms and deterioration of
health in the homozygous Pax6 conditional mice that were Cre
positive and treated with tamoxifen (named CPTD6 mice).
Diabetic symptoms were not found in any control animals, except
in one of the heterozygous Pax6 conditional, Cre-positive
tamoxifen treated females, supporting the possibility of increased
diabetes susceptibility in PAX6 heterozygous aniridia patients
[20,27,32]. In the four weeks following Pax6 inactivation no
obvious neurological, olfactory or eye abnormalities were
observed, but more detailed histological analysis of some of these
tissues is in progress.
We show that production of the endocrine hormones insulin,
glucagon and somatostatin is strongly reduced in response to the
adult stage inactivation of Pax6. The direct regulation of these
hormones by Pax6 in the developing and neonatal pancreas is
well-established [7,12], and specific Pax6 binding sites have been
described in the regulatory regions of these genes [7,12,33,34].
Pax6 expression in adult islets of Langerhans has also been
documented [19,21], and is confirmed by our data, which
demonstrates that the continued presence of Pax6 is essential for
endocrine hormone production. There is increasingly convincing
evidence that glucose handling and insulin production are also
disturbed in adult rodents and humans who carry heterozygous
PAX6 mutations [19,20,21,28]. This suggests that not only is
PAX6 essential for pancreatic endocrine maintenance, but that
correct dosage of the protein is required for this role, as it is for
some other transcription factors associated with diabetes, such as
HNF1A and HNF4A, in which heterozygous mutations have been
found in a significant portion of MODY cases [35].
The islet markers Isl1 and Nkx2.2 retain a normal expression
pattern in the Pax6 deleted pancreas by immunohistochemistry,
indicating there is no gross morphological change in the islets
following Pax6 removal. Interestingly, we observe loss of Pdx1 and
Nkx6.1 expression in the Pax6 deleted pancreata, indicating Pax6
acts upstream of these genes in adult pancreas. In contrast, during
embryonic development Pdx1 acts upstream of Pax6 [9,36], and
no Pax6 expression is detected in the pancreas of Pdx1 knock-out
mice [9]. Developmental regulators are well known to cross-
regulate in reciprocal feedback loops in many systems and, while
at this stage it is unclear whether Pdx1 is a direct Pax6 target, Pax6
and Pdx1 may be tightly connected through reciprocal wiring into
the gene regulatory network for pancreas development and
maintenance [37].
Previous work has shown that loss of Pdx1 expression in adult
beta-cells disrupts key proteins involved in glucose sensing,
including Glut2 (Slc2a2) and the proinsulin processing machinery,
PC1/3 and PC2 [31]. Loss of Pax6 expression in the adult
pancreas, as shown here, also affects these functions. Mice with
a Glut2 null mutation develop diabetes [38], demonstrating the
requirement for this sugar transporter. It is unclear whether the
near total loss of Glut2 expression in our experimental animals is
due directly to loss of Pax6 activity or as an indirect consequence
of losing Pdx1 expression. Gosmain et al identified putative
consensus Pax6 binding sites upstream of the Glut2 start site by
in silico prediction, suggesting Pax6 could regulate Glut2 directly,
but no binding was found by EMSA [34], and Pax6 binding site
predictions by Hidden Markov Modelling did not reveal Glut2 as
a target gene [39]. Chromatin immunoprecipitation studies with
Pax6 and Pdx1 antibodies in pancreatic islet cells will be required
to resolve this issue.
Another feature of type 2 diabetes is hyperpronisulinaemia [40]
which often reflects a defect in the proinsulin processing pathway.
Prohormone convertases PC1/3 and PC2 together with Carboxy-
peptidase E catalyse this cleavage sequence [41]. Expression levels
of PC1/3 were severely reduced in Pax6 null animals, but PC2
was less affected, a situation reminiscent to that observed in the
FRID1 mice and conditional Pdx1 null mice [31], and this
suggests that Pax6 may directly regulate components of the insulin
processing machinery, or could do so indirectly through regulation
of Pdx1 and/or components of the FGF signaling family. Our
Figure 5. Glucose sensing, hormone processing and the
exocrine compartment. (A, B) Expression of the glucose transporter
Glut2 (Slc2a2), localised at the endocrine cell surface, is lost in CPTD6
mice. (C, D) Cytoplasmic expression of the prohormone processing
factor PC1/3 (Pcsk1) is absent in CPTD6 mice. (E, F). Expression of the
processing factor PC2 (Pcsk2) and (G, H) the exocrine enzyme amylase
are not affected.
doi:10.1371/journal.pone.0054173.g005
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in vivo observations are in agreement with data obtained in a recent
study using Pax6 RNAi in a rat b-cell model [34], although we
observed little, or no difference in PC2 expression, while
a moderate reduction was reported in the rat b-cell model.
Aniridia patients with PAX6 mutations have been reported to have
elevated proinsulin levels, even when not frankly diabetic; and
PC1/3 levels are reduced in heterozygous Pax6 mutant mice, with
some evidence for direct binding of Pax6 to upstream elements of
PC1/3 [20,42]. In contrast, it is suggested that PC2 may only be
an indirect target of Pax6 [12,43], but it is interesting to note that
PC2 expression was significantly reduced in one Pax6 mutant
mouse line [44].
In contrast to the near complete loss in insulin expression,
severe reduction in glucagon- and moderate reduction in
somatostatin positive cells, we observed a striking increase in
ghrelin-expressing cells. The appearance of ghrelin producing cells
in the Pax6-null islets of the CPTD6 mice suggests that Pax6 may
be implicated in the control of ghrelin expression in the adult
pancreas. Reduction in insulin and glucagon expressing cells has
also been observed when Pax6 is inactivated during development,
both in Pax6 mutants and in a pancreas specific knock-out of the
gene [44,45]. Dames et al. also observed an increase in ghrelin
positive cells and a quantitatively similar reduction in glucagon
positive cells and suggested a developmental lineage switch of
alpha to epsilon cells in the absence of Pax6. It is difficult to say
whether the ghrelin-positive cells, observed when Pax6 is turned
off in adulthood, are derived by transdifferentiation from alpha
cells. The majority of the newly ghrelin-expressing cells are
positioned at the periphery of the islet, like alpha cells, but further
analysis is required to determine the origin of these cells. Ghrelin is
predominantly expressed in the stomach in adulthood and is
involved in regulating food intake, hepatic glucose production and
preventing glucose disposal in muscle and adipose tissue [46]. The
predicted increase in ghrelin production, coupled with the marked
reduction in insulin expression, may explain the rapid onset of
diabetes in our animals [47]. Animals in which either the ghrelin
gene or the ghrelin receptor has been silenced have improved
glucose tolerance [48,49,50], indicating a distinct role for ghrelin
in glucose homeostasis.
Figure 6. Upregulation of Ghrelin expression in CPTD6 islets. Immunohistochemistry for ghrelin (B, E, H, K, N, Q) was performed in
combination with insulin (A, D), glucagon (G, J), and somatostatin (M, P). Merged images with DAPI nuclear counter-staining are shown (C, F, I, L,
O, R) on pancreata from control (A, B, C, G, H, I, M, N, O) and CPTD6 (D, E, F, J, K, L, P, Q, R) mice. Levels of insulin and glucagon expression are
markedly reduced or lost in the majority of islet cells of CPTD6 mice in comparison with the controls, while the number of somatostatin positive cells
appears more moderately reduced. Very few, if any, ghrelin positive cells can be found in the islets of control adult mice (B, C, H, I, N, O). In contrast,
strong staining is observed in many cells of the CPTD6 pancreata, located predominantly around the periphery of the islets. Images are representative
of at least four animals from each group. Scale bars, 50 mm. (S, T, U, V). Quantification of the relative numbers of hormone expressing cells in the islets
of Langerhans of control and CPTD6 animals shown as the percentage of immunofluorescence positive cells per total number of DAPI positive cells.
(S) Insulin producing cells (control 72% .19% CPTD6), (T) Glucagon producing cells (control 11.4% .5.3% CPTD6) (U) Somatostatin producing cells
(control 11.6% .9.5% CPTD6), and (V) Ghrelin producing cells (control 0.6% .20.6% CPTD6).
doi:10.1371/journal.pone.0054173.g006
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Our studies add an adult requirement for Pax6 to its well-known
developmental role [4,5]. The scale of its many pleiotropic
functions is reflected in the complex cis-regulatory architecture of
the Pax6 genomic locus [51–55]. While the essential role of Pax6
for embryonic development and post-natal viability obscures its
role in adult maintenance of target organs, and its potential
involvement in adult-onset diseases such as diabetes, this role
would be unmasked by mutations or variations in the cis-elements
that drive Pax6 expression in these adult tissues. Currently the cis-
elements required for expression in the adult pancreas are
unknown, but following our demonstration of the essential role
for Pax6 in pancreas homeostasis, their identification has gained
greater importance. Two elements located upstream of the Pax6
P0 promoter are known to drive expression in the pancreas during
embryonic development [51,53,54], but it is unknown if these
remain active during adult life, and adult expression may well
depend on further cis-elements in the locus. Sequence variation in
these elements could constitute a risk factor for diabetes [42].
In conclusion, we show that loss of Pax6 in the adult islet affects
the expression of multiple target genes involved in the mainte-
nance of pancreatic endocrine function and glucose handling, and
results in the rapid appearance of diabetic symptoms in previously
healthy mice.
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